Board of Directors
Board of Directors
Elisabeth has a MSc in Biochemical Engineering from the Royal Institute of Technology and a MBA from Uppsala University.
She has 35 years+ experience from management within pharmaceutical R&D, as project manager, Head of Department, COO and CEO. Elisabeth has vast international experience from Big Pharma and from smaller companies, both public and non-public. She has recently served as the CEO and COO of OxThera AB. Previous positions include Diamyd Medical AB, OctaPharma AB, Metcon Medicin AB and Pharmacia Corporation. Previous Board positions include Pharmalink AB, KaroBio AB and Cobra Biologics AB.
Other Appointments
Elisabeth is an independent advisor specializing at biopharma due diligence work for investors and companies, supporting potential investments.
Elisabeth is an elected member of the Royal Swedish Academy of Engineering and will starting from 2027 chair the Life Science and Biotechnology section.
Other Board Appointments
Board member of BioSource Europe AB.
Holds 38,933 shares in Epicyt Pharma AB
Johan has a Ph.D. in Neurochemistry and Neurotoxicology from Stockholm University and completed post-doctoral training in pharmacology and physiology at the New York University and the University of Oxford, and in business and administration at Warwick University Business School.
Other Appointments
Johan is an independent advisor to investors and pharma companies. Johan served as Calliditas Therapeutics’ Chief Scientific Officer until October 2025. Prior to that, he served as SVP Licensing, IP & Legal 2017-2019 at Calliditas Therapeutics AB and as Chief Executive Officer from 2007 to 2017 at Pharmalink AB. He previously served in various managerial and executive roles at Karo Bio AB, Pharmacia Corporation and NeuroNova AB and has in total more than 35 years of experience from drug discovery and development, and business development.
Other Board Appointments
Board member Oncoinvent ASA and Eken Advisors Aktiebolag.
Holds 142,295 shares in Epicyt Pharma AB.
Sara holds a M.Sc. in Biotechnology and Business Development from Chalmers University of Technology.
She has more than 15 years of experience in life science innovation, business development and investment analysis, with a particular focus on building and financing early-stage biotechnology and pharmaceutical companies.
Other appointments
Sara works as a Business Developer at GU-ventures.
Other board appointments
Agmine Pharma AB and Runa Bio AB, Implexion Pharma AB and Endoriz AB.
GU Ventures holds 190,409 shares.
Anders holds a Bachelor of Economics in business administration from Webster University, Genève.
Anders has been the CEO of several companies within the biotech and financial sector. For 10 years, Anders held the position as CEO of Isofol Medical AB (publ), developing the cancer drug candidate arfolitixorin.
Other Board appointments
Board member of Albonja AB, Akkumula AB and Särö Golf Club.
Other appointments
Anders is currently CEO of Mindforce Game Lab.
Holds 322,480 shares in Epicyt Pharma AB through Albonja AB
Martin is an Endocrinologist and Internal Medicine Specialist and holds a PhD from Lund University, Sweden, and an MBA from Copenhagen Business School, Denmark.
Martin has been Professor at Lund University Diabetes Center, Sweden, VP and Head of Clinic at Steno Diabetes Center, Denmark, CVP of Clinical Pharmacology and Translational Medicine at Novo Nordisk A/S, Denmark, and is currently SVP of Clinical Science at the Novo Nordisk Foundation, Denmark.
Other Appointments
CEO of WeightSpot AB.
Holds 10,834 shares in Epicyt Pharma AB.
Ville is a Medical Doctor and PhD and holds a position as an Associate Professor at the Sahlgrenska Academy, University of Gothenburg and Consultant Surgeon at the Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.
Ville is a specialist in bariatric surgery and group leader of a research group conducting research on the mechanisms of action of bariatric surgery on metabolism as well as its adverse effects, e. g. on bone metabolism. He is together with Professor Lars Fändriks the inventor behind Epicyt Pharma AB.
Other Board Appointments
Board member of the Swedish Society of Bariatric and Metabolic Surgery (Svensk Förening för Obesitas och metabol Kirurgi, SFOK) and board member of Dr Arnt Vestbys Research Foundation that appoints the yearly “Doctoral thesis of the Year” prize at the Sahlgrenska Academy at the University of Gothenburg.
Other Appointments
CEO of Villus Medical AB.
Holds 256,000 shares in Epicyt Pharma AB through Villus Medical AB.
